RxDoctor Payments Data

Robert Morasch, MD

Family Medicine · Walla Walla, WANPI 1669478137

Payments from drug & device makers

$1,256in general payments, 2019–2025

Across 59 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$257
  • Abbott$176
  • GSK$168
  • AbbVie$126
  • Novo Nordisk$95
  • Boehringer Ingelheim$68
  • plus $366 from 11 others

What the payments were for

  • Food & beverage$1,256100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,256 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$228,340
Medicare patients
377
Services billed
1,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$72,530
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$40,825
JardianceEmpagliflozin24$27,321
JanuviaSitagliptin Phosphate24$22,306
XareltoRivaroxaban59$18,836
FarxigaDapagliflozin Propanediol17$15,169
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$9,347
Novolog FlexpenInsulin Aspart18$5,388
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,528
Atorvastatin Calcium407$4,106
Metoprolol Succinate208$3,102
Levothyroxine Sodium200$2,231
Omeprazole160$2,225
Losartan Potassium191$2,026
Potassium Chloride77$1,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$168$40,82540 claims
Boehringer IngelheimJardiance$68$27,32124 claims
AstraZenecaFarxiga$257$15,16917 claims
AbbVieSynthroid$126$60321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Walla Walla

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →